Trial Profile
A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Ozanimod (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms True North OLE; True North open-label extension (OLE) study
- Sponsors Celgene Corporation
- 08 Mar 2024 This trial has been Completed in Germany as per European Clinical Trials Database record.
- 01 Feb 2024 This trial has been completed in Slovakia as per European Clinical Trials Database record
- 22 Dec 2023 This trial has been completed in Greece according to European Clinical Trials Database record.